Home Tags Metastatic triple-negative breast cancer

Tag: metastatic triple-negative breast cancer

ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain...

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the brain and treat patients with...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...

Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...